KR101254382B1 - 6ｈ-디벤조［ｂ,ｅ］옥세핀 유도된 비-스테로이드성 염류코르티코이드 수용체 길항제 - Google Patents

6ｈ-디벤조［ｂ,ｅ］옥세핀 유도된 비-스테로이드성 염류코르티코이드 수용체 길항제 Download PDF

Info

Publication number
KR101254382B1
KR101254382B1 KR1020107013601A KR20107013601A KR101254382B1 KR 101254382 B1 KR101254382 B1 KR 101254382B1 KR 1020107013601 A KR1020107013601 A KR 1020107013601A KR 20107013601 A KR20107013601 A KR 20107013601A KR 101254382 B1 KR101254382 B1 KR 101254382B1
Authority
KR
South Korea
Prior art keywords
mol
formula
compound
methyl
ylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107013601A
Other languages
English (en)
Korean (ko)
Other versions
KR20100082866A (ko
Inventor
콘스탄티노스 가바르디나스
프라브하카르 콘다지 자드하브
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101254382(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20100082866A publication Critical patent/KR20100082866A/ko
Application granted granted Critical
Publication of KR101254382B1 publication Critical patent/KR101254382B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107013601A 2007-12-19 2008-12-09 6ｈ-디벤조［ｂ,ｅ］옥세핀 유도된 비-스테로이드성 염류코르티코이드 수용체 길항제 Expired - Fee Related KR101254382B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
US61/014,776 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
KR20100082866A KR20100082866A (ko) 2010-07-20
KR101254382B1 true KR101254382B1 (ko) 2013-04-15

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107013601A Expired - Fee Related KR101254382B1 (ko) 2007-12-19 2008-12-09 6ｈ-디벤조［ｂ,ｅ］옥세핀 유도된 비-스테로이드성 염류코르티코이드 수용체 길항제

Country Status (33)

Country Link
US (1) US7994164B2 (cg-RX-API-DMAC10.html)
EP (2) EP2537845B1 (cg-RX-API-DMAC10.html)
JP (1) JP5562866B2 (cg-RX-API-DMAC10.html)
KR (1) KR101254382B1 (cg-RX-API-DMAC10.html)
CN (1) CN101903377B (cg-RX-API-DMAC10.html)
AR (1) AR069554A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008343524B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0820805A2 (cg-RX-API-DMAC10.html)
CA (1) CA2710409C (cg-RX-API-DMAC10.html)
CL (1) CL2008003600A1 (cg-RX-API-DMAC10.html)
CO (1) CO6300953A2 (cg-RX-API-DMAC10.html)
DK (1) DK2235007T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2010000185A (cg-RX-API-DMAC10.html)
EA (1) EA017668B1 (cg-RX-API-DMAC10.html)
EC (2) ECSP10010266A (cg-RX-API-DMAC10.html)
ES (2) ES2396605T3 (cg-RX-API-DMAC10.html)
GT (1) GT201000179A (cg-RX-API-DMAC10.html)
HR (1) HRP20120916T1 (cg-RX-API-DMAC10.html)
IL (1) IL206353A (cg-RX-API-DMAC10.html)
MA (1) MA31910B1 (cg-RX-API-DMAC10.html)
MX (1) MX2010006911A (cg-RX-API-DMAC10.html)
MY (1) MY150474A (cg-RX-API-DMAC10.html)
NZ (1) NZ586300A (cg-RX-API-DMAC10.html)
PE (1) PE20091057A1 (cg-RX-API-DMAC10.html)
PL (1) PL2235007T3 (cg-RX-API-DMAC10.html)
PT (1) PT2235007E (cg-RX-API-DMAC10.html)
RS (1) RS52594B (cg-RX-API-DMAC10.html)
SI (1) SI2235007T1 (cg-RX-API-DMAC10.html)
TN (1) TN2010000292A1 (cg-RX-API-DMAC10.html)
TW (1) TWI431010B (cg-RX-API-DMAC10.html)
UA (1) UA100131C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009085584A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201004257B (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
EP2568986B1 (en) 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
ME03316B (me) 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
JP2017531684A (ja) * 2014-11-21 2017-10-26 イーライ リリー アンド カンパニー 腎障害の治療のための１，２−ベンゾチアゾール化合物
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2018054357A1 (zh) * 2016-09-24 2018-03-29 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
EP4118235B1 (en) 2020-03-11 2026-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CN117510398A (zh) * 2023-11-02 2024-02-06 上海诺丁太生物科技有限公司 一种高光学纯度(3r,4r)/(3s,4s)-n-boc-4-氨基-3-羟基哌啶的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034574A2 (en) * 1980-02-14 1981-08-26 Fagersta AB A method of preventing corrosion in boiler-plant equipment
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
FR2603713B1 (fr) * 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
ES2260497T7 (es) * 2001-11-21 2009-11-05 Millennium Pharmaceuticals, Inc. Antagonistas de receptores de quimioquininas y metodos de uso de los mismos.
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
DE602004014640D1 (de) * 2003-12-19 2008-08-07 Lilly Co Eli Tricyclische modulatoren von nuklearen steroidhormonrezeptoren
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
SG161261A1 (en) 2004-11-10 2010-05-27 Incyte Corp Lactam compounds and their use as pharmaceuticals
ES2375877T3 (es) 2006-10-31 2012-03-07 Pfizer Products Inc. Compuestos de pirazolina como antagonistas de receptores de mineralocorticoides.
JP2010522732A (ja) 2007-03-29 2010-07-08 ナームローゼ・フエンノートチヤツプ・オルガノン 鉱質コルチコイド受容体アンタゴニスト
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009094157A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034574A2 (en) * 1980-02-14 1981-08-26 Fagersta AB A method of preventing corrosion in boiler-plant equipment
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2004052847A3 (en) 2002-06-26 2004-09-10 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators

Also Published As

Publication number Publication date
MA31910B1 (fr) 2010-12-01
PT2235007E (pt) 2013-01-22
HRP20120916T1 (hr) 2012-12-31
AR069554A1 (es) 2010-02-03
EP2537845A1 (en) 2012-12-26
EA201070762A1 (ru) 2010-12-30
ES2459318T3 (es) 2014-05-09
UA100131C2 (uk) 2012-11-26
MY150474A (en) 2014-01-30
AU2008343524B2 (en) 2012-03-08
DOP2010000185A (es) 2010-09-15
PE20091057A1 (es) 2009-07-20
ZA201004257B (en) 2011-11-30
PL2235007T3 (pl) 2013-03-29
TN2010000292A1 (en) 2011-11-11
CN101903377A (zh) 2010-12-01
NZ586300A (en) 2012-06-29
CN101903377B (zh) 2014-07-09
JP2011507868A (ja) 2011-03-10
EP2235007B1 (en) 2012-10-31
HK1144284A1 (en) 2011-02-11
CA2710409C (en) 2012-11-06
CO6300953A2 (es) 2011-07-21
TWI431010B (zh) 2014-03-21
BRPI0820805A2 (pt) 2015-06-16
ECSP12012048A (es) 2012-08-31
RS52594B (sr) 2013-04-30
EA017668B1 (ru) 2013-02-28
ECSP10010266A (es) 2010-07-30
GT201000179A (es) 2012-04-16
CL2008003600A1 (es) 2010-02-19
KR20100082866A (ko) 2010-07-20
ES2396605T3 (es) 2013-02-22
SI2235007T1 (sl) 2013-01-31
EP2537845B1 (en) 2014-03-19
US7994164B2 (en) 2011-08-09
TW200930721A (en) 2009-07-16
WO2009085584A1 (en) 2009-07-09
IL206353A0 (en) 2010-12-30
CA2710409A1 (en) 2009-07-09
US20090163472A1 (en) 2009-06-25
EP2235007A1 (en) 2010-10-06
IL206353A (en) 2014-06-30
DK2235007T3 (da) 2012-12-17
MX2010006911A (es) 2010-10-05
AU2008343524A1 (en) 2009-07-09
JP5562866B2 (ja) 2014-07-30

Similar Documents

Publication Publication Date Title
KR20100082866A (ko) 6ｈ-디벤조[ｂ,ｅ]옥세핀 유도된 비-스테로이드성 염류코르티코이드 수용체 길항제
KR20230026450A (ko) 항암 약물로서의 퀴녹살린 유도체
EP2491024B1 (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
JP7214053B2 (ja) 糖尿病治療に有用な６－メトキシ－３，４－ジヒドロ－１ｈ－イソキノリン化合物
TWI444376B (zh) 脯胺醯胺吡啶化合物、其藥學組成物及醫藥用途
CA2751901C (en) Mineralocorticoid receptor antagonist and methods of use
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡
JP6938485B2 (ja) 選択的ｎｒ２ｂアンタゴニスト
BRPI0619422A2 (pt) derivados de cromona úteis como antagonistas de receptores vr1
HK1144284B (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
US20040204402A1 (en) Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170409

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170409